Literature DB >> 15760392

Impact of MHC class II incompatibility on localization of mononuclear cell infiltrates to the bronchiolar compartment of orthotopic lung allografts.

Shinji Nakashima1, T Rinda Soong, Karen Fox-Talbot, Zhiping Qian, Salma Rahimi, Barbara A Wasowska, Charles A Rohde, Sabrina Chen, Joe G N Garcia, William M Baldwin.   

Abstract

Chronic pathological changes in transplanted lungs are unique because they center on the airways. We examined the relative role of MHC class I and II antigens in causing bronchial pathology in orthotopic lung transplants to rats maintained on cyclosporin A (CsA). Transplants mismatched for MHC class II antigens had significantly more peri-bronchiolar infiltrates than MHC class I incompatible transplants. No significant increase in infiltrates was found in lung transplants incompatible for MHC class I plus II antigens compared to MHC class II antigens alone. Immunohistochemistry demonstrated that MHC class II antigen expression was confined to macrophages in MHC class I incompatible transplants, but was upregulated on bronchial epithelium in transplants with MHC class II incompatibilities. Vascular endothelium was notably devoid of MHC class II antigen expression in all transplants. However, both peri-bronchial and peri-vascular infiltrates were frequently cuffed by alveolar macrophages and type II pneumocytes that expressed MHC class II antigens. PCR analysis demonstrated that IFN-gamma and regulated on activation, normal T cells expressed and secreted (RANTES) were upregulated in MHC class II incompatible transplants. Thus, MHC class II incompatible orthotopic lung transplants in rats maintained on CsA immunosuppression undergo a bronchiolcentric upregulation of alloantigens.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15760392      PMCID: PMC1351097          DOI: 10.1111/j.1600-6143.2005.00782.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  40 in total

1.  Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation.

Authors:  T J Kroshus; V R Kshettry; K Savik; R John; M I Hertz; R M Bolman
Journal:  J Thorac Cardiovasc Surg       Date:  1997-08       Impact factor: 5.209

2.  Immunohistochemical characterization of inflammatory and proliferative events during chronic rejection in rat lung allografts.

Authors:  A G Lee; F M Wagner; A Giaid; M F Chen; Q Hamid; C Serrick; H Shennib
Journal:  Transplantation       Date:  1997-08-15       Impact factor: 4.939

3.  Expression of the chemokine RANTES by a human bronchial epithelial cell line. Modulation by cytokines and glucocorticoids.

Authors:  C Stellato; L A Beck; G A Gorgone; D Proud; T J Schall; S J Ono; L M Lichtenstein; R P Schleimer
Journal:  J Immunol       Date:  1995-07-01       Impact factor: 5.422

4.  Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group.

Authors:  S A Yousem; G J Berry; P T Cagle; D Chamberlain; A N Husain; R H Hruban; A Marchevsky; N P Ohori; J Ritter; S Stewart; H D Tazelaar
Journal:  J Heart Lung Transplant       Date:  1996-01       Impact factor: 10.247

5.  Intrapulmonary production of RANTES during rejection and CMV pneumonitis after lung transplantation.

Authors:  G Monti; A Magnan; M Fattal; B Rain; M Humbert; J L Mege; M Noirclerc; P Dartevelle; J Cerrina; G Simonneau; P Galanaud; D Emilie
Journal:  Transplantation       Date:  1996-06-27       Impact factor: 4.939

6.  Interferon-gamma deficiency prevents coronary arteriosclerosis but not myocardial rejection in transplanted mouse hearts.

Authors:  H Nagano; R N Mitchell; M K Taylor; S Hasegawa; N L Tilney; P Libby
Journal:  J Clin Invest       Date:  1997-08-01       Impact factor: 14.808

7.  Induction of MHC class II antigens on rat bronchial epithelial cells by interferon-gamma and its effect on antigen presentation.

Authors:  T Suda; A Sato; W Sugiura; K Chida
Journal:  Lung       Date:  1995       Impact factor: 2.584

8.  Obliterative bronchiolitis after lung and heart-lung transplantation. An analysis of risk factors and management.

Authors:  K Bando; I L Paradis; S Similo; H Konishi; K Komatsu; T G Zullo; S A Yousem; J M Close; A Zeevi; R J Duquesnoy
Journal:  J Thorac Cardiovasc Surg       Date:  1995-07       Impact factor: 5.209

9.  Improved outcome of rat lung transplantation with modification of the nonsuture external cuff technique.

Authors:  A Reis; A Giaid; C Serrick; H Shennib
Journal:  J Heart Lung Transplant       Date:  1995 Mar-Apr       Impact factor: 10.247

10.  Assessment of pathological changes associated with chronic allograft rejection and tolerance in two experimental models of rat lung transplantation.

Authors:  Y Matsumura; A Marchevsky; X J Zuo; R M Kass; J M Matloff; S C Jordan
Journal:  Transplantation       Date:  1995-06-15       Impact factor: 4.939

View more
  1 in total

Review 1.  Mechanisms involved in antibody- and complement-mediated allograft rejection.

Authors:  Barbara A Wasowska
Journal:  Immunol Res       Date:  2010-07       Impact factor: 2.829

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.